A new drug called daraxonrasib has shown promising results in extending the lives of patients with advanced pancreatic cancer, according to findings presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The experimental medication, which targets a genetic mutation present in 90% of pancreatic cancer cases, nearly doubled survival rates in clinical trials.
Core Facts & Immediate Action
The study, published in the New England Journal of Medicine, found that patients taking daraxonrasib lived a median of 13.2 months compared to 6.7 months for those receiving standard chemotherapy. The drug, a RAS inhibitor, reduces the risk of death by 60% in patients with metastatic pancreatic cancer who had previously undergone treatment. Researchers described the results as a significant breakthrough in a disease that has historically had limited treatment options.
Deeper Dive & Context
Study Details
The trial randomly assigned 500 patients to either receive daraxonrasib or additional chemotherapy. The drug, taken as a daily pill, showed fewer severe side effects and improved quality of life for recipients. Patients on the medication stayed on treatment longer, reporting less pain and tumor shrinkage.
Expert Reactions
Dr. Zev Wainberg of UCLA, who led the study, called the findings a "very large step forward," though he noted the drug does not cure the cancer. Dr. Rachna Shroff of the University of Arizona Cancer Center, who was not involved in the research, described the results as "unprecedented," saying she "actually started crying" upon seeing the data.
Broader Implications
Pancreatic cancer is one of the deadliest cancers, with over half of patients dying within three months of diagnosis due to late detection. Until now, chemotherapy has been the primary treatment option. The success of daraxonrasib suggests a potential shift in how the disease is managed, offering hope for longer survival and better quality of life for patients.
Next Steps
The findings mark the first substantial advantage of a drug over chemotherapy for pancreatic cancer. Further research is needed to confirm long-term benefits and refine treatment protocols.